Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Array BioPharma
Biotech
The AKT is over: Roche dumps phase 3 prostate cancer prospect
The Swiss drug developer has dropped a phase 3 prostate cancer trial—and sent its acute graft-versus-host disease prospect packing at the same time.
Nick Paul Taylor
Feb 2, 2023 4:20am
Pfizer drops cardiology drug after phase 3 fails futility check
Aug 4, 2022 9:20am
Treating melanoma by turning off a common mutation
Jan 31, 2019 1:50pm
AstraZeneca’s selumetinib flops in thyroid cancer
Jul 26, 2018 4:27am
Merck's ERK inhibitor shows promise against resistant cancers
Feb 22, 2018 3:57pm
Array’s encorafenib/binimetinib beats Roche’s Zelboraf in phase 3
Feb 6, 2018 10:27am
